Терапевтический архив (Jan 2024)

Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review

  • Iuliia G. Samoilova,
  • Olga E. Vaizova,
  • Anastasia E. Stankova,
  • Mariia V. Matveeva,
  • Daria V. Podchinenova,
  • Dmitry A. Kudlay,
  • Anastasiia A. Borozinets,
  • Tatyana A. Filippova,
  • Ivan R. Grishkevich,
  • Anastasia V. Partala,
  • Diana A. Gerasimova

DOI
https://doi.org/10.26442/00403660.2024.01.202553
Journal volume & issue
Vol. 96, no. 1
pp. 63 – 67

Abstract

Read online

The review addresses publications on genetic polymorphisms that potentially impact the effectiveness of therapy with hypoglycemic drugs of the dipeptidyl peptidase-4 inhibitor group. The literature was searched in the PubMed database from 2017 to 2023. Polymorphisms of several genes (GLP1R, TCF7L2, DPP-4, KCNQ1, KCNJ11, PNPLA3, PRKD1) are associated with the pharmacokinetic values and efficacy of dipeptidyl peptidase-4 inhibitors, which may be promising for personalizing the treatment of patients with type 2 diabetes mellitus.

Keywords